)
Relay Therapeutics (RLAY) investor relations material
Relay Therapeutics Jefferies London Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Strategic execution and clinical progress
Focused on executing phase III trials for RLY-2608, a PI3K alpha mutant selective inhibitor, with robust financial resources supporting ongoing and future programs.
Advancing triplet regimens for earlier breast cancer treatment lines and expanding into PI3K alpha-driven vascular malformations, NRAS, and Fabry disease programs.
Confident in achieving competitive progression-free survival (PFS) in second-line settings, targeting a 2–3 month PFS improvement over Capivasertib.
Transitioned to a 400-mg BID Fed dosing regimen for RLY-2608, maintaining similar or improved pharmacokinetic coverage compared to previous dosing.
Monitoring and management strategies for hyperglycemia are in place, with no anticipated impact from Fed dosing and less stringent at-home glucose monitoring requirements than comparators.
Competitive landscape and efficacy benchmarks
Current second-line PFS benchmarks remain at 5.5–7 months; RLY-2608 shows a 10–11 month PFS, considered highly competitive.
Capivasertib, despite lower PFS, has gained market share due to a better safety profile.
Early data from competitors like Scorpion and Roche show potential but raise concerns about toxicity and tolerability, especially regarding LFT signals.
Triplet regimens in the frontline setting are being explored, with efficacy bars set by Roche and Inavolisib at 14–15 months PFS, but with complex administration and safety considerations.
Study design, patient selection, and future directions
Phase III studies are designed with stricter inclusion criteria, likely enrolling healthier, less pretreated patients, which may help maintain PFS outcomes.
Ongoing and future studies will test efficacy in broader populations, including those with higher A1C, but initial pivotal trials focus on prediabetic patients for consistency.
Signals of extended PFS (up to 18 months) in kinase mutation cohorts suggest potential for further targeted studies.
Next Relay Therapeutics earnings date
Next Relay Therapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)